Results 91 to 100 of about 34,445,663 (284)

Benefits and Harms of Once-weekly Glucagon-like peptide-1 receptor agonist treatments. A systematic review and network meta-analysis

, 2015
Benefits and Harms of Once-weekly Glucagon-like peptide-1 receptor agonist treatments.
Zin Zin Htike (7682996), Melanie J. Davies (7155500), Francesco Zaccardi (285809), David R. Webb (200468), Kamlesh Khunti (171607)   +4 more
core   +5 more sources

Tinjauan atas Glucagon-like peptide-1 receptor agonist

Cermin Dunia Kedokteran, 2020
<p>GLP-1 receptor agonist secara struktur mirip hormon alami GLP-1 yang memiliki efek incretin, namun degradasinya dapat dicegah oleh DPP-4. Saat ini terdapat 8 jenis yang terdiri dari exenatide, exenatide ER, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide injeksi, dan semaglitode oral.
openaire   +1 more source

Empirically Defining “Recurrent” Inappropriate Compensatory Behaviors: Differentiating Binge Eating Disorder From Bulimia Nervosa‐Spectrum Disorders

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective For multiple disorders, DSM‐5‐TR criteria include “recurrent” engagement in behaviors—for example, in the criteria for binge‐eating disorder (BED), “binge eating is not associated with the recurrent use of inappropriate compensatory behavior.”—without operationalizing how frequently a behavior needs to occur to be considered ...
Sophie R. Abber, Dan V. Blalock, Renee D. Rienecke, Philip S. Mehler, Alan Duffy, Jamie Manwaring, Maryrose Bauschka, Kimberly Anderson, Harry A. Brandt, Craig Johnson, Timothy Brewerton, Thomas E. Joiner, Lauren N. Forrest   +12 more
wiley   +1 more source

Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies

Obesity is a chronic disease associated with multiple health risks. Multimodal treatments including lifestyle interventions, pharmacotherapies and bariatric surgery should be the standard of care for obesity management. Bariatric surgery remains the most
Kaivalya ABBURI (22136206), Dimitrios Papamargaritis (20339727), Eka MELSON (22136209), Alexander D MIRAS (22136212)   +3 more
core   +5 more sources

Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease

Annual Review of Medicine
Glucagon-like peptide 1 receptor (GLP-1R) agonists were originally developed as treatments for diabetes and subsequently evolved into weight management medications. These drugs have recently been shown to demonstrate remarkable efficacy in cardiovascular disease, kidney disease, and heart failure with preserved ejection fraction (HFpEF). In this review,
Tatsuro, Ibe, Barry A, Borlaug
openaire   +2 more sources

Nociceptin/orphanin FQ – NOP receptor system: novel genetic and pharmacological tools [PDF]

, 2012
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. In cells expressing the NOP receptor N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents.
Molinari, Stefano
core  

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia

, 2015
Ofer Yanay,1,2 Adam L Bailey,3 Kelly Kernan,1 Jerry J Zimmerman,1,2 William R Osborne1 1Department of Pediatrics, University of Washington, 2Division of Pediatric Critical Care Medicine, Seattle Children's Hospital, Seattle, WA, 3Medical Scientist ...
Osborne WR, Yanay O, Bailey AL, Zimmerman JJ, Kernan K   +4 more
core  

Survodutide - Novel Anti Obesity Drug

JK Science
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore, Sana Malik, Amarjeet Singh, Vishal R Tandon, Annil Mahajan   +4 more
doaj  

Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report

Journal of International Medical Research
Semaglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes mellitus and management of obesity. Associations of glucagon-like peptide-1 receptor agonist use with psychiatric adverse events and suicidal behavior have
Anisija Stojkovska, Polona Rus Prelog, Anja Kokalj Palandacic   +2 more
doaj   +1 more source